Sagent Pharma (SGNT) to Acquire Remaining Interest in Chengdu
Tweet Send to a Friend
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced an agreement to acquire the 50% interest of its joint venture partner, Chengdu Kanghong ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE